Experience of the use of mitotan in the combined treatment of adrenocortical cancer


如何引用文章

全文:

详细

In this article we both summarized the knowledge about epidemiology, pathophysiology and diagnosis of adrenocortical cancer (ACC) and discussed treatment issues and main management mistakes. Despite the poor prognosis of the disease, options for the advanced treatment of ACC patients with differentiated approach can significantly improve the overall and disease-free survival rate. In this connection the question arises about the multidisciplinary approach in the treatment of ACC patients with the inclusion of maximum and timely set measures: surgical, drug (mitotan therapy, chemotherapy, replacement and supportive therapy) and radiation therapy.

作者简介

I. Dedov

Endocrine Research Center

Moscow, 117036, Russian Federation

G. Melnichenko

Endocrine Research Center

Moscow, 117036, Russian Federation

Dmitry Beltsevich

Endocrine Research Center

Email: belts67@gmail.com
MD, PhD, Chief Researcher of the Department of Surgery of the Endocrine Research Center Moscow, 117036, Russian Federation

B. Alexeev

P.A. Hertsen Moscow Oncology Research Institute

Moscow, 125284, Russian Federation

V. Gorbunova

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

N. Perevodchikova

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

A. Rayhman

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

G. Gildeeva

I.M. Sechenov First Moscow State Medical University

Moscow, 119991, Russian Federation

参考

  1. Berruti A., Baudin E., Gelderblom H. et al. Adrenal cancer: ESMO (European Society for Medical Oncology) Clinical Practice Guidelines for diagnosis, treatment and follow-up on behalf of the ESMO Guidelines Working Group. Ann. Oncol. 2012; 23: 131-8.
  2. NCCN Clinical Practice Guidelines in Oncology, Neuroendocrine Tumor. Version 1.2014.
  3. Мельниченко Г.А., Стилиди И.С., Горбунова В.А., Алексеев Б.Я., Бельцевич Д.Г., Райхман А.О. и др. Российские клинические рекомендации по диагностике и лечению адренокортикального рака. 2015.
  4. Fassnacht M., Arlt W., Bancos I., Dralle H., Newell-Price J., Sahdev A. et al. Management of Adrenal Incidentalomas. A European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. 2016.
  5. Else T., Kim A., Sabolch A., Raymond V., Kandathil A., Caoili E. et al. Adrenocortical carcinoma. Endocrine Rev. 3201; 45: 282-326.
  6. Young W.F., Jr. The incidentally discovered adrenal mass. N. Engl. J. Med. 2007;356:601-10.
  7. Бельцевич Д.Г., Кузнецов Н.С., Солдатова Т.В., Ванушко В.Э. Инциденталома надпочечников. Эндокринная хирургия. 2009; 4(1): 19-23.
  8. Bovio S., Cataldi A., Reimondo G. et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J. Endocrinol. Invest. 2006; 29: 298-302.
  9. Cawood T.J., Hunt P.J., O’Shea D., Cole D., Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Literature review. Eur. J. Endocrinol. 2009; 161: 513-27.
  10. Pacak K. Preoperative management of the pheochromocytoma patient. J. Clin. Endocrinol. Metab. 2007; 92: 4069-79.
  11. Дедов И.И., Бельцевич Д.Г., Кузнецов Н.С., Мельниченко Г.А. Феохромоцитома. Москва: Практическая медицина. 2005: 47-70.
  12. An Endocrine Society Clinical Practice Guidelines. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. J. Clin. Endocrinol. Metab. 2008; 93(9): 3266-81.
  13. Трошина Е.А., Бельцевич Д.Г., Молашенко Н.В. Диагностика и дифференциальная диагностика первичного гиперальдостеронизма. Клин. мед. 2009; (5): 15-20.
  14. Nieman L.K., Biller B.M.K., Findling J.W. et al. The diagnosis of Cushing’s syndrome:an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2008; 93(5): 1526-40.
  15. Tsagarakis S., Vassiliadi D., Thalassinos N. Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J. Endocrinol. Invest. 2006; 29: 471-82.
  16. Szolar D.H., Korobkin M., Reittner P. et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 2005; 234: 479.
  17. Metser U., Miller E., Lerman H. et al. 18F-FDG PET/CT in the evaluation of adrenal masses. J. Nucl. Med. 2006; 47(1): 32-7.
  18. Blake M., Prakash P., Cronin C. PET/CT for adrenal assessment. Am. J. Roentgenol. 2010; 195(2): 195.
  19. Mackie G.C., Shulkin B.L., Ribeiro R.C. et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2006; 91: 2665.
  20. Leboulleux S., Dromain C., Bonniaud G. et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J. Clin. Endocrinol. Metab. 2006; 91: 920.
  21. Deandreis D., Leboulleux S., Caramella C. et al. FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm. Cancer. 2011; 6(2): 354-62.
  22. Welch T.J., Sheedy P.F. II, Stephens D.H. et al. Percutaneous adrenal biopsy: review of a 10-year experience. Radiology. 1994; 193: 341-4.
  23. Arellano R.S., Harisinghani M.G., Gervais D.A. et al Imageguided percutaneous biopsy of the adrenal gland: review of indications, technique, and complications. Curr. Probl. Diagn. Radiol. 2003; 32: 3-10.
  24. Harisinghani M.G., Maher M.M., Hahn P.F. et al. Predictive value of benign percutaneous adrenal biopsies in oncology patients. Clin. Radiol. 2002; 57: 898-901.
  25. Dackiw A.P., Lee J.E., Gagel R.F., Evans D.B. Adrenal cortical carcinoma. World J. Surg. 2001; 25: 914-26.
  26. Ng L., Libertino J.M. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J. Urol. 2003; 169: 5-11.
  27. Miller B.S., Gauger P.G., Hammer G.D. et al. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch. Surg. 2010; 395: 955.
  28. Fassnacht M., Johanssen S., Quinkler M. et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009; 115: 243-50.
  29. Allolio B., Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J. Clin. Endocrinol. Metab. 2006; 91(6): 2027-37.
  30. Филимонюк А.В., Харченко Н.В., Леонов Б.И., Смирнова Е.А., Антонов А.К., Смелкова Н.И. Непосредственные и отдаленные результаты хирургического лечения больных адренокортикальным раком. Вестник новых медицинских технологий (электронное издание). 2013; 1 [Электронный ресурс].
  31. Donatini G., Caiazzo R., Do Cao Ch. et al. Long-term survival after adrenalectomy for stage I/II Adrenocortical Carcinoma (ACC): A retrospective comparative cohort study of laparoscopic versus open approach. Ann. Surg. Oncol. 2014; 21: 284-91.
  32. McCauley L.R., Nguyen M.M. Laparoscopic radical adrenalectomy for cancer: long-term outcomes. Curr. Opin. Urol. 2008; 18: 134-8.
  33. Miller B.S., Gauger P.G., Hammer G.D., Doherty G.M. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery. 2012; 152: 1150-7.
  34. Weiss L.M. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol. 1984; 8(3): 163-9.
  35. Lau S.K., Weiss L.M. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum. Pathol. 2009; 40(6): 757-68.
  36. Бохян В.Ю., Павловская А.И., Губина Г.И., Стилиди И.С. Клиническая оценка гистологических систем диагностики адренокортикальных опухолей. Арх.в пат. 2015; 77(3): 17-22.
  37. van Slooten H., Schaberg A., Smeenk D., Moolenar A.J. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer. 1985; 55(4): 766-73.
  38. Филиппова О.В., Хмельницкая Н.М. Адренокортикальный рак: клинические проявления и морфологическая диагностика. Медицинский альманах. 2011; (5): 113-6.
  39. Hahner S., Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr. Opin. Invest. Drugs. 2005; 6: 386-94.
  40. Schteingart D.E. Conventional and novel strategies in the treatment of adrenocortical cancer. Braz. J. Med. Biol. Res. 2000; 33: 1197-200.
  41. Cordon-Cardo C., O’Brien J.P., Boccia J. et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 1990; 38: 1277-87.
  42. Flynn S.D., Murren J.R., Kirby W.M. et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery. 1992; 112: 981-6.
  43. Goldstein L.J., Galski H., Fojo A. et al. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 1989; 81: 116-24.
  44. Fridborg H., Larsson R., Juhlin C., Rastad J., Akerstrom G., Backlin K., Nygren P. P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells. Anticancer Res. 1994; 14: 1009-16.
  45. Haak H.R., van Seters A.P., Moolenaar A.J., Fleuren G.J. Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur. J. Cancer. 1993; 29A: 1036-8.
  46. Dickstein G. Is there a role of low dose of mitotane as adjuvant therapy in adrenocortical carcinoma? J. Clin. Endocrinol. Metab. 1999; 84: 1488-9.
  47. Vassilopoulou-Sellin R., Guinee V.F., Klein M.J. et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1993; 71: 3119-23.
  48. Terzolo M., Angeli A., Fassnacht M.Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med. 2007; 356(23): 2372-80.
  49. Clinical Trials Gov. Identifier NCT00777244, Start 2008, Update 2013.
  50. Fassnacht M., Libé R., Kroiss M., Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat. Rev. Endocrinol. 2011; 7: 323-35.
  51. Lubitz J.A., Freeman L., Okun R. Mitotane use in inoperable adrenalcortical carcinoma. J.A.M.A. 1973; 223: 1109-12.
  52. van Slooten H., Moolenaar A.J., van Seters A.P., Smeenk D. The treatment of adrenocortical carcinoma with o,p_-DDD: prognostic implications of serum level monitoring. Eur. J. Cancer Clin. Oncol. 1984; 20: 47-53.
  53. Haak H.R., Hermans J., van de Velde C.J.et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br. J. Cancer. 1994; 69: 947-51.
  54. Baudin E., Pellegriti G., Bonnay M. et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p_DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 2001; 92: 1385-92.
  55. Heilmann P., Wagner P., Nawroth P.P., Ziegler R. [Therapy of the adrenocortical carcinoma with Lysodren (o,p’-DDD). Therapeutic management by monitoring o,p_-DDD blood levels]. Med Klin. 2001; 96: 371-7.
  56. Becker D., Schumacher O.P. o,p’DDD therapy in invasive adrenocortical carcinoma. Ann. Intern. Med. 1975; 82: 677-9.
  57. Boven E., Vermorken J.B., van Slooten H., Pinedo H.M. Complete response of metastasized adrenal cortical carcinoma with o,p_-DDD. Case report and literature review. Cancer. 1984; 53: 26-9.
  58. Krzisnik C., Petric G., Jereb B. Complete response of metastatic adrenal cortical carcinoma to o,p_-DDD in a child. Pediatr. Hematol. Oncol. 1988; 5: 65-9.
  59. Lim M.C., Tan Y.O., Chong P.Y., Cheah J.S. Treatment of adrenal cortical carcinoma with mitotane: outcome and complications. Ann. Acad. Med. Singapore. 1990; 19: 540-4.
  60. Decker R.A., Kuehner M.E. Adrenocortical carcinoma. Am. Surg. 1991; 57: 502-13.
  61. Remond S., Bardet S., Charbonnel B. Complete and lasting remission of a metastatic malignant adrenocortical carcinoma under treatment with OP-_DDD alone. Presse Med. 1992; 21: 865.
  62. Ilias I., Alevizaki M., Philippou G., Anastasiou E., Souvatzoglou A. Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane. J. Endocrinol. Invest. 2001; 24: 532-5.
  63. Allolio B., Hahner S., Weismann D., Fassnacht M. Management of adrenocortical carcinoma. Clin. Endocrinol. (Oxf.). 2004; 60: 273-87.
  64. Hague R.V., May W., Cullen D.R. Hepatic microsomal enzyme induction and adrenal crisis due to o,p_DDD therapy for metastatic adrenocortical carcinoma. Clin. Endocrinol. (Oxf.). 1989; 31: 51-7.
  65. Fassnacht M., Terzolo M., Allolio B. et al. Combination chemotherapy in advanced adrenocortical carcinoma. FIRM-ACT Study Group. N. Engl. J. Med. 2012; 366(23): 2189-97.
  66. Fassnacht M., Kroiss M., Allolio B. Update in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2013; 98(12): 4551-64.
  67. Schulick R.D., Brennan M.F.. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann. Surg. Oncol. 1999; 6(8): 719-26.
  68. Icard P., Chapuis Y., Andreassian B. et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery. 1992; 112(6): 972-9.
  69. Bellantone R., Ferrante A., Boscherini M. et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997; 122: 1212-8.
  70. Porpiglia F., Fiori C., Scarpa R.M. et al. The role of surgery in the management of recurrent adrenocortical carcinoma: results of a retrospective study. Eur. Urol. 2009; 8 (4, Suppl.): 305.
  71. Le Tourneau C., Hoims C.H., Zarwan C et al. Avelumab (MSM0010718C; anti-PD-L1) in patients with advanced adrenocortical carcinoma from the JAVELIN solid tumor Ib trial: Safety and clinical activity. J. Cin. Oncol. 2016; 34(15): 4516.

版权所有 © Eco-Vector, 2016


 


##common.cookie##